Moomoo AI 已提取核心信息
On January 8, 2024, Novavax, Inc. updated investors, reaffirming its guidance for the full year 2023 expenses to be between $1.15 billion and $1.25 billion. The company is currently finalizing its financial results for the year ended December 31, 2023, and has stated that the preliminary financial data provided is based on the information available and may be subject to change. The data has not been audited or reviewed by Ernst & Young LLP, the company's independent registered public accounting firm, or any other independent accountants. Novavax cautions that the actual results may differ materially from the preliminary data and advises investors not to place undue reliance on this preliminary information. Additionally, Novavax presented strategic and business updates at the 42nd Annual J.P. Morgan Healthcare Conference, with the presentation available on the company's website. The company also included forward-looking statements in its report and presentation, warning that actual results could vary significantly due to various risks and uncertainties.
On January 8, 2024, Novavax, Inc. updated investors, reaffirming its guidance for the full year 2023 expenses to be between $1.15 billion and $1.25 billion. The company is currently finalizing its financial results for the year ended December 31, 2023, and has stated that the preliminary financial data provided is based on the information available and may be subject to change. The data has not been audited or reviewed by Ernst & Young LLP, the company's independent registered public accounting firm, or any other independent accountants. Novavax cautions that the actual results may differ materially from the preliminary data and advises investors not to place undue reliance on this preliminary information. Additionally, Novavax presented strategic and business updates at the 42nd Annual J.P. Morgan Healthcare Conference, with the presentation available on the company's website. The company also included forward-looking statements in its report and presentation, warning that actual results could vary significantly due to various risks and uncertainties.
2024年1月8日，Novavax, Inc.向投资者通报了最新情况，重申其2023年全年支出在11.5亿美元至12.5亿美元之间的指导方针。该公司目前正在敲定截至2023年12月31日的年度的财务业绩，并表示提供的初步财务数据基于现有信息，可能会发生变化。该数据未经过安永会计师事务所、该公司的独立注册会计师事务所或任何其他独立会计师的审计或审查。Novavax警告说，实际业绩可能与初步数据存在重大差异，并建议投资者不要过分依赖这些初步信息。此外，Novavax在第42届摩根大通医疗保健年度会议上介绍了战略和业务最新情况，该演讲可在公司网站上公布。该公司还在其报告和陈述中纳入了前瞻性陈述，警告说，由于各种风险和不确定性，实际业绩可能会有很大差异。
2024年1月8日，Novavax, Inc.向投资者通报了最新情况，重申其2023年全年支出在11.5亿美元至12.5亿美元之间的指导方针。该公司目前正在敲定截至2023年12月31日的年度的财务业绩，并表示提供的初步财务数据基于现有信息，可能会发生变化。该数据未经过安永会计师事务所、该公司的独立注册会计师事务所或任何其他独立会计师的审计或审查。Novavax警告说，实际业绩可能与初步数据存在重大差异，并建议投资者不要过分依赖这些初步信息。此外，Novavax在第42届摩根大通医疗保健年度会议上介绍了战略和业务最新情况，该演讲可在公司网站上公布。该公司还在其报告和陈述中纳入了前瞻性陈述，警告说，由于各种风险和不确定性，实际业绩可能会有很大差异。
有用
没用